257 related articles for article (PubMed ID: 23161787)
1. Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.
Di Stefano AL; Enciso-Mora V; Marie Y; Desestret V; Labussière M; Boisselier B; Mokhtari K; Idbaih A; Hoang-Xuan K; Delattre JY; Houlston RS; Sanson M
Neuro Oncol; 2013 May; 15(5):542-7. PubMed ID: 23161787
[TBL] [Abstract][Full Text] [Related]
2. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
[TBL] [Abstract][Full Text] [Related]
3. Replication of GWAS identifies RTEL1, CDKN2A/B, and PHLDB1 SNPs as risk factors in Portuguese gliomas patients.
Viana-Pereira M; Moreno DA; Linhares P; Amorim J; Nabiço R; Costa S; Vaz R; Reis RM
Mol Biol Rep; 2020 Feb; 47(2):877-886. PubMed ID: 31721021
[TBL] [Abstract][Full Text] [Related]
4. Genetic risk profiles identify different molecular etiologies for glioma.
Simon M; Hosking FJ; Marie Y; Gousias K; Boisselier B; Carpentier C; Schramm J; Mokhtari K; Hoang-Xuan K; Idbaih A; Delattre JY; Lathrop M; Robertson LB; Houlston RS; Sanson M
Clin Cancer Res; 2010 Nov; 16(21):5252-9. PubMed ID: 20847058
[TBL] [Abstract][Full Text] [Related]
5. An Updated and Comprehensive Meta-Analysis of Association Between Seven Hot Loci Polymorphisms from Eight GWAS and Glioma Risk.
Wu Q; Peng Y; Zhao X
Mol Neurobiol; 2016 Sep; 53(7):4397-405. PubMed ID: 26243184
[TBL] [Abstract][Full Text] [Related]
6. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide association study identifies five susceptibility loci for glioma.
Shete S; Hosking FJ; Robertson LB; Dobbins SE; Sanson M; Malmer B; Simon M; Marie Y; Boisselier B; Delattre JY; Hoang-Xuan K; El Hallani S; Idbaih A; Zelenika D; Andersson U; Henriksson R; Bergenheim AT; Feychting M; Lönn S; Ahlbom A; Schramm J; Linnebank M; Hemminki K; Kumar R; Hepworth SJ; Price A; Armstrong G; Liu Y; Gu X; Yu R; Lau C; Schoemaker M; Muir K; Swerdlow A; Lathrop M; Bondy M; Houlston RS
Nat Genet; 2009 Aug; 41(8):899-904. PubMed ID: 19578367
[TBL] [Abstract][Full Text] [Related]
8. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
Sabha N; Knobbe CB; Maganti M; Al Omar S; Bernstein M; Cairns R; Çako B; von Deimling A; Capper D; Mak TW; Kiehl TR; Carvalho P; Garrett E; Perry A; Zadeh G; Guha A; Sidney Croul
Neuro Oncol; 2014 Jul; 16(7):914-23. PubMed ID: 24470545
[TBL] [Abstract][Full Text] [Related]
9. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.
Walsh KM; Rice T; Decker PA; Kosel ML; Kollmeyer T; Hansen HM; Zheng S; McCoy LS; Bracci PM; Anderson E; Hsuang G; Wiemels JL; Pico AR; Smirnov I; Molinaro AM; Tihan T; Berger MS; Chang SM; Prados MD; Lachance DH; Sicotte H; Eckel-Passow JE; Wiencke JK; Jenkins RB; Wrensch MR
Neuro Oncol; 2013 Aug; 15(8):1041-7. PubMed ID: 23733245
[TBL] [Abstract][Full Text] [Related]
10. Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci.
Labreche K; Kinnersley B; Berzero G; Di Stefano AL; Rahimian A; Detrait I; Marie Y; Grenier-Boley B; Hoang-Xuan K; Delattre JY; Idbaih A; Houlston RS; Sanson M
Acta Neuropathol; 2018 May; 135(5):743-755. PubMed ID: 29460007
[TBL] [Abstract][Full Text] [Related]
11. Genetic causes of glioma: new leads in the labyrinth.
Melin B
Curr Opin Oncol; 2011 Nov; 23(6):643-7. PubMed ID: 21825990
[TBL] [Abstract][Full Text] [Related]
12. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
13. Pertinence of glioma and single nucleotide polymorphism of TERT, CCDC26, CDKN2A/B and RTEL1 genes in glioma: a meta-analysis.
Wu Y; Zhou J; Zhang J; Tang Z; Chen X; Huang L; Liu S; Chen H; Wang Y
Front Oncol; 2023; 13():1180099. PubMed ID: 37746290
[TBL] [Abstract][Full Text] [Related]
14. Interaction between 5 genetic variants and allergy in glioma risk.
Schoemaker MJ; Robertson L; Wigertz A; Jones ME; Hosking FJ; Feychting M; Lönn S; McKinney PA; Hepworth SJ; Muir KR; Auvinen A; Salminen T; Kiuru A; Johansen C; Houlston RS; Swerdlow AJ
Am J Epidemiol; 2010 Jun; 171(11):1165-73. PubMed ID: 20462933
[TBL] [Abstract][Full Text] [Related]
15. New insights into susceptibility to glioma.
Liu Y; Shete S; Hosking FJ; Robertson LB; Bondy ML; Houlston RS
Arch Neurol; 2010 Mar; 67(3):275-8. PubMed ID: 20212223
[TBL] [Abstract][Full Text] [Related]
16. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma.
Chai RC; Zhang KN; Chang YZ; Wu F; Liu YQ; Zhao Z; Wang KY; Chang YH; Jiang T; Wang YZ
Carcinogenesis; 2019 Oct; 40(10):1229-1239. PubMed ID: 31157866
[TBL] [Abstract][Full Text] [Related]
17. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
18. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.
Rice T; Zheng S; Decker PA; Walsh KM; Bracci P; Xiao Y; McCoy LS; Smirnov I; Patoka JS; Hansen HM; Hsuang G; Wiemels JL; Tihan T; Pico AR; Prados MD; Chang SM; Berger MS; Caron A; Fink S; Kollmeyer T; Rynearson A; Voss J; Kosel ML; Fridley BL; Lachance DH; Eckel-Passow JE; Sicotte H; O'Neill BP; Giannini C; Wiencke JK; Jenkins RB; Wrensch MR
Neuro Oncol; 2013 May; 15(5):535-41. PubMed ID: 23361564
[TBL] [Abstract][Full Text] [Related]
19. Genetic advances in glioma: susceptibility genes and networks.
Liu Y; Shete S; Hosking F; Robertson L; Houlston R; Bondy M
Curr Opin Genet Dev; 2010 Jun; 20(3):239-44. PubMed ID: 20211558
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
Labussière M; Di Stefano AL; Gleize V; Boisselier B; Giry M; Mangesius S; Bruno A; Paterra R; Marie Y; Rahimian A; Finocchiaro G; Houlston RS; Hoang-Xuan K; Idbaih A; Delattre JY; Mokhtari K; Sanson M
Br J Cancer; 2014 Nov; 111(10):2024-32. PubMed ID: 25314060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
